Author: Hicks, S.; Pohl, K.; Neeman, T.; McNamara, H.; Parsons, K.; He, J.-S.; Ali, S.; Nazir, S.; Rowntree, L.; Nguyen, T.; Kedzierska, K.; Doolan, D.; Vinuesa, C.; Cook, M.; Coatsworth, N.; Myles, P.; Kurth, F.; Sander, L.; Gruen, R.; Mann, G.; George, A.; Gardiner, E.; Cockburn, I.
Title: A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting Cord-id: f86jlksx Document date: 2020_9_14
ID: f86jlksx
Snippet: Estimates of seroprevalence of SARS-CoV-2 antibodies have been hampered by inadequate assay sensitivity and specificity. Using an ELISA-based approach to that combines data about IgG responses to both the Nucleocapsid and Spike-receptor binding domain antigens, we show that near-optimal sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia
Document: Estimates of seroprevalence of SARS-CoV-2 antibodies have been hampered by inadequate assay sensitivity and specificity. Using an ELISA-based approach to that combines data about IgG responses to both the Nucleocapsid and Spike-receptor binding domain antigens, we show that near-optimal sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (0 to 0.72%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay.
Search related documents:
Co phrase search for related documents- acid testing and low community transmission: 1
Co phrase search for related documents, hyperlinks ordered by date